



Protein glycation – biomarkers of metabolic dysfunction and early-stage decline in health in the era of precision medicine

Naila Rabbani^{a,b,**}, Paul J. Thornalley^{c,*}

^a Department of Basic Medical Science, College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar

^b Biomedical & Pharmaceutical Research Unit, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar

^c Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, P.O. Box 34110, Doha, Qatar

ARTICLE INFO

Keywords:

Glycated hemoglobin
Fructosamine
Methylglyoxal
Diabetes
Chronic kidney disease
Machine learning

ABSTRACT

Protein glycation provides a biomarker in widespread clinical use, glycated hemoglobin HbA_{1c} (A1C). It is a biomarker for diagnosis of diabetes and prediabetes and of medium-term glycemic control in patients with established diabetes. A1C is an early-stage glycation adduct of hemoglobin with glucose; a fructosamine derivative. Glucose is an amino group-directed glycation agent, modifying N-terminal and lysine sidechain amino groups. A similar fructosamine derivative of serum albumin, glycated albumin (GA), finds use as a biomarker of glycemic control, particularly where there is interference in use of A1C. Later stage adducts, advanced glycation endproducts (AGEs), are formed by the degradation of fructosamines and by the reaction of reactive dicarbonyl metabolites, such as methylglyoxal. Dicarbonyls are arginine-directed glycation agents forming mainly hydroimidazolone AGEs. Glucosepane and pentosidine, an intense fluorophore, are AGE covalent crosslinks. Cellular proteolysis of glycated proteins forms glycated amino acids, which are released into plasma and excreted in urine. Development of diagnostic algorithms by artificial intelligence machine learning is enhancing the applications of glycation biomarkers. Investigational glycation biomarkers are in development for: (i) healthy aging; (ii) risk prediction of vascular complications of diabetes; (iii) diagnosis of autism; and (iv) diagnosis and classification of early-stage arthritis. Protein glycation biomarkers are influenced by heritability, aging, decline in metabolic, vascular, renal and skeletal health, and other factors. They are applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype. They are thereby likely to find continued and expanding clinical use, including in the current era of developing precision medicine, reporting on multiple pathogenic processes and supporting a precision medicine approach.

1. Introduction – protein glycation in the clinical setting

Protein glycation is the spontaneous, non-enzymatic reaction of proteins with simple reducing sugars and related metabolites. In the clinical setting, the major glycation agent is glucose which reacts with amino groups of N-terminal and lysine residues of proteins to form an initial Schiff's base, with following rearrangement to form N-(1-deoxy-D-fructos-1-yl)amino acids or fructosamines [1]. For lysine residues, the adduct is N_ε-1-deoxyfructosyl-lysine (FL), with analytical surrogate, furosine [2] (Fig. 1a). Glycation of proteins by glucose to the fructosamine stage is classified as early glycation. In later stage reactions, fructosamine degrades to stable endstage adducts called advanced

glycation endproducts (AGEs). Other important glycation agents are reactive α -oxoaldehyde metabolites, particularly methylglyoxal (MG), glyoxal and 3-deoxyglucosone. Dicarbonyls from mainly arginine-derived hydroimidazolone AGEs as the dominant product, typically accounting for >90% total glycation adducts formed [3,4]. Other minor glycation adducts include N_ε-carboxymethyl-lysine (CML) and N_ω-carboxymethyl-arginine (CMA) formed from glyoxal, and N_ε-carboxyethyl-lysine (CEL) from MG. Glucose and MG are precursors of major quantitative early-stage glycation adducts and AGEs, FL and hydroimidazolone MG-H1, respectively. The formation of AGEs, CML from FL and pentosidine from pentose precursors, involves oxidation and these processes are called glycooxidation (Fig. 1b). Glycation adducts are present as two major forms: glycation adduct residues of proteins –

* Corresponding author. Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, P.O. Box 34110, Doha, Qatar.

** Corresponding author. Department of Basic Medical Science, College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.

E-mail addresses: n.rabbani@qu.edu.qa (N. Rabbani), pthornalley@hbku.edu.qa (P.J. Thornalley).

<https://doi.org/10.1016/j.redox.2021.101920>

Received 3 January 2021; Received in revised form 16 February 2021; Accepted 22 February 2021

Available online 26 February 2021

2213-2317/© 2021 The Author(s).

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abbreviations

Ab	antibody	GCKR	glucokinase regulator
A1C	glycated hemoglobin HbA _{1c}	GFR	glomerular filtration rate
ACE	angiotensin converting enzyme	GG	glycosylation gap
AGE	advanced glycation endproduct	G-H1	glyoxal-derived hydroimidazolone
ARB	angiotensin receptor blocker	Glo1	glyoxalase 1
ASD	autism spectrum disorder	GSP	glucosepane
BMI	body mass index	GWAS	genome-wide association studies
CAC	coronary artery calcification	HDL	high density lipoprotein
CCP	citrullinated cyclic peptide	LC-MS/MS	liquid chromatography-tandem mass spectrometry
CEL	N _ε -carboxyethyl-lysine	LDL	low density lipoprotein
CIMT	carotid intima-media thickness	LR	likelihood ratio
CKD	chronic kidney disease	MetSO	methionine sulfoxide
CMA	N _ω -carboxymethyl-arginine	MG	methylglyoxal
CML	N _ε -carboxymethyl-lysine	MG-H1	methylglyoxal-derived hydroimidazolone
CVD	cardiovascular disease	NBT	nitroblue tetrazolium
DCCT	Diabetes Control and Complications Trial	NFK	N-formylkynurenine
3DG-H	3-deoxyglucosone-derived hydroimidazolone	3-NT	3-nitrotyrosine
DT	dityrosine	OA	osteoarthritis
EDRF	early decline in renal function	PAD	peripheral artery disease
ELOVL2	elongation of very long-chain fatty acids protein-2	PTC	renal proximal tubular epithelial cells
FADS	polymorphism of fatty acid desaturase	SNP	single nucleotide polymorphism
FL	N _ε -1-deoxyfructosyl-lysine	RA	rheumatoid arthritis
FN3K	fructosamine 3-kinase	ROS	reactive oxygen species
G6PD	glucose-6-phosphate dehydrogenase	T1DM	type 1 diabetes mellitus
GA	glycated albumin	T2DM	type 2 diabetes mellitus
		TER	transcapillary escape rate

also called “protein-bound glycation adducts” and glycated amino acids or glycation free adducts. Cellular proteolysis forms glycation free adducts which are released into plasma and excreted in urine. There is also absorption of glycation free adducts and small glycated peptides from digestion of glycated proteins in food [5]. Processes of formation and metabolic transit of protein glycation are summarised schematically (Fig. 1c). Protein glycation occurs in the cellular and extracellular compartments. Glycated proteins are also ingested and those degraded to small glycated peptides and free adducts are absorbed in the portal vein. Albumin cycles from plasma into interstitial fluid, lymph and returns to plasma – with some leakage through renal glomeruli and return to venous circulation by the renal albumin retrieval pathway of proximal tubular epithelial cells (PTCs) [6]. The major route of excretion of glycation adducts is as free adducts in urine, with minor excretion in urinary albumin, other proteins and peptides. Glycation free adducts with molecular mass <500 Da pass readily through the glomerular filter into glomerular filtrate and are reabsorbed and secreted in the renal proximal tubules, likely by amino acid transporters, producing usually high and characteristic fractional excretions [7,8].

In this review, we describe the clinical diagnostic application of glycation adducts as biomarkers. Glycation adducts may be biomarkers used for diagnosis, risk of developing a health disorder or disease and monitoring of the response to treatment. The steady-state levels of glycation adduct residues of proteins reflect the rates of formation, degradation and repair of the glycated protein in the compartments where the protein substrate is located [9]. Glycation adducts provide reports on different aspects of metabolism [9] (Table 1). The levels of glycation free adducts in plasma reflects the balance between fluxes of free adducts released into the vasculature from tissues (including absorption from digested food in the portal vein) and renal clearance [10], increasing profoundly in experimental nephrectomy and clinical renal failure [7, 11]. The urinary flux of glycation free adducts reflects the total body flux of formation of glycation adducts with a contribution from glycation free adducts absorbed from food [7,11,12]. Factors affecting the level of glycated protein biomarker are: concentration of the protein substrate,

concentration of the glycating agent and duration of exposure to it, and turnover and repair and replacement of the glycated protein [5]. Other non-glycation based physiological factors provide interferences in biomarker reporting of physiological glycation [13]. Robust measurement of glycation adducts in the clinical chemistry laboratory has been challenging which recent advances in application of stable isotopic dilution analysis LC-MS/MS have overcome [9,14]. The strength and weakness of different analytical methods and overview of steps in development and validation for clinical use are summarised in Table 2. With optimized methodologies and protocols now available, protein glycation provides unique and valuable clinical and investigational biomarkers.

2. Glycated hemoglobin A1C

Glycated hemoglobin, HbA_{1c} or A1C, is widely used for the diagnosis and monitoring of glycemic control of diabetes, in both patients with type 1 diabetes mellitus (T1DM) and patients with type 2 diabetes mellitus (T2DM). Current guidelines advise A1C is measured at least biannually in patients with diabetes [15]. A1C is also used for the diagnosis of prediabetes – a condition that precedes development of T2DM [16]. It is formed by the reaction of glucose with unglycated hemoglobin, HbA₀. The major adduct formed is the fructosamine derivative of the N-terminal valine residue of the beta-chain, βval-1, with also glucose modification at αlys-61 and βlys-66 [17–19]. There are other minor forms of glycated hemoglobin resolved from A1C in conventional cation exchange chromatography analysis used in clinical chemistry, representing <1% total Hb: HbA_{1a1}, HbA_{1a2} and HbA_{1b}, which are βval-1 adducts of fructose-1,6-bisphosphate, glucose-6-phosphate and pyruvate, respectively, and HbA_{1d} (aldimine Schiff's base) and HbA_{1e} (fructosamine adduct of αval-1) [20–22]. The steady-state level of A1C *in vivo* is influenced by deglycation of glycation adducts by fructosamine 3-kinase (FN3K) [23,24], red blood cell lifespan (mean 120 days) and glycemic control over the previous 90–120 days [25]. A1C is a weighted measure of mean blood glucose concentration during

Table 1
Biomarker characteristics of protein glycation adducts.

Glycation adduct	Reporter feature (precursor)	Comment
FL ^a	Glycemic control (glucose)	Major early-stage glycation adduct. Repaired intracellularly by fructosamine 3-phosphokinase [24]. Free adduct absorbed after digestion of food proteins [121].
MG-H1	Dicarbonyl stress (methylglyoxal)	Major AGE. Linked to increased fasting and postprandial glucose exposure, unscheduled glycolysis, insulin resistance and cardiovascular disease [4,12,90,119,122]. Free adduct absorbed after digestion of food proteins [12]. Good stability in samples with delayed processing for epidemiological studies [73]
CML	Glycooxidation glycemic control/(FL and others)	Major AGE. Formed by the oxidative degradation of FL and other sources. CML/FL ratio is an indicator of oxidative stress [123]. Free adduct absorbed after digestion of food proteins [124].
GSP	Glycemic control/glycation crosslinking (FL)	Major glycation crosslink [75]. Major glycation adduct released from joint proteins during early-stage development of osteoarthritis [116]. Good stability in samples with delayed processing for epidemiological studies [73].
Pentosidine	Pentosephosphate pathway activity (pentose metabolite)	Low level pentose sugar-derived glycation crosslink and intense fluorophore. Considered to reflect pentosephosphate pathway activity [125]. Skin collagen pentosidine accounts for 30% variation in SAF [126]
Pyrraline	AGE exposure from food (cooked food)	Glucose-derived AGE formed at high temperatures of culinary processing; originating only from food [127,128]. Urinary pyrraline excretion is linked to amount of AGE absorbed from food [12].

^a Also applies to N-(1-deoxy-D-fructos-1-yl)amino acids (fructosamine). Abbreviation: SAF, skin autofluorescence.

diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and increased risk of cardiovascular disease (CVD). As a biomarker of glycemic control, A1C is considered a modifiable risk factor for the chronic vascular complications of diabetes. Decrease of A1C by intensive treatment with hypoglycemic drugs is associated with decreased risk of development of diabetic microvascular complications [34–36] and decreased progression of CVD in patients with T1DM [37,38] (Table 3). A1C was also associated with all-cause mortality in non-diabetic and diabetic subjects [39].

There is a strong genetic influence of A1C. Genes influencing A1C are in metabolic pathways influencing glycemic status, red blood cells and others – including FN3K which catalyzes the deglycation of glycosylated hemoglobin [23,32]. In non-diabetic subjects, 62% of population variation in A1C is explained by genetics and the remainder is attributable to the influence of environment (23%) and age (14%). Genetic influence of A1C also extended in patients with diabetes [40]. A1C may underestimate the glycemic status of subjects with sickle cell anemia and patients with renal failure on dialysis [30,31] (Table 4).

3. Glycated albumin and serum fructosamine

Glycation of serum albumin by glucose produces glycated albumin (GA) which is also a clinical biomarker of glycemic control. It is increasingly preferred where interferences in A1C apply – see above.

The major sites of glycation are, in order of reactivity: asp-1, lys-525, lys-199 and lys-439 [41]. The extent of albumin glycation in healthy human subjects is 11–16%, increasing 2–3 fold in patients with diabetes [42]. Albumin has a half-life of ca. 20 days, and provides a report on glucose control over 14–20 days prior to blood sampling [43]. GA shows 48% genetic influence in population variation [44,45] (Tables 3 and 4).

Albumin is secreted into plasma by the liver. It leaks from the vascular into interstitial fluid at 5% of total plasma pool per h – the albumin transcapillary escape rate (TER). It returns to plasma via lymph. Albumin leaking through renal glomeruli is returned to the venous circulation by the renal albumin retrieval pathway where GA may be preferentially excreted [6,46,47] (Fig. 1c). Given the decreased concentrations of albumin and glucose in the interstitial fluid compared to plasma, the rate of glycation of albumin by glucose is ca. 4-fold lower in the interstitial fluid compared to plasma (Fig. 2a) [48]. Change in albumin TER in hypertension, obesity, diabetes, acute inflammatory disease and peripheral artery disease (PAD) may provide an interference in use of GA as a biomarker of glycemic control [49–54]. Decreased synthesis, plasma concentration and catabolism of albumin in patients with cirrhosis likely explains the 2-fold increase of GA without change in glycemic status [10,46]. It was initially proposed from experimental studies that AGE-modified albumin is extracted from plasma by the liver [55]. Clinical studies of levels of endogenous AGE-modified albumin in hepatic artery, portal vein and hepatic vein did not support this [10]. Albumin ligands used in experimental studies had high, supra-physiological extents of glycation and abnormally high increased net negative charge which bind hepatic scavenger receptors for cellular uptake [55–57]. Endogenous AGE-modified albumin clinically or albumin modified by AGEs *in vitro* to physiological extent showed no binding of the scavenger receptor and limited extraction in the liver [10,58,59]. The cellular uptake and proteolysis of FL- and AGE-modified albumin is rather proposed to occur in multiple tissues, similar to that of unglycated albumin [10]. Recent studies suggest glycosylated proteins are directed for cellular proteolysis by the unfolded protein response [60,61].

A further interference is through effects of renoprotective drug treatment on leakage of albumin through the renal glomerular filter (Fig. 1c). Patients with early-stage diabetic nephropathy, micro-albuminuria, are treated with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). This decreases the size of the pores of the renal glomerular filter, decreasing leakage of albumin and particularly GA into the glomerular filtrate. Treatment with ARB, Irbesartan, increased in GA by 66–72% without change in A1C [62].

A glycation biomarker related to GA is serum fructosamine – a measure of total serum protein glycation by glucose. It is determined as the rate of reduction of serum protein using nitroblue tetrazolium (NBT) at pH 10.8 [63], reports on glycemic control over 10–14 days prior to sampling [43] and likely has similar interferences to GA. The concentration of serum fructosamine in healthy human subjects was $230 \pm 26 \mu\text{M}$ [64] but the absolute calibration is challenging; different fructosamines reducing NBT at different rates [63,65]. Measurement of serum fructosamines or “Fructosamine test” is low cost and in widespread clinical use.

Both serum fructosamine and GA correlate positively with A1C [64]. Cohen et al. introduced a derivative variable called the glycosylation gap (GG) which is the difference between measured A1C and A1C predicted from the fructosamine based on the A1C-fructosamine regression equation [66]. GG may predict progression of diabetic nephropathy [67]. From the above considerations, increased albumin TER and renoprotective drug treatment may produce negative and positive GGs, respectively [48,62]. GG also has strong genetic influence (Table 4).

4. Glycated skin collagen and other fructosamine-modified proteins

FL residue content of skin collagen increases with age of healthy

Table 2

Major analytical methodologies for glycation biomarkers in clinical practice and research. Steps to clinical translation.

MAJOR ANALYTICAL METHODOLOGIES			
Glycation analyte	Analytical methodology	Comment	Reference
<i>Clinical practice application</i>			
Glycated hemoglobin	Immunoassay (recognizing glycated N-terminus of β -chain).	Rapid and high sample throughput. Automated in clinical chemistry analyzers.	[129]
HbA _{1c}	Cation exchange chromatography with absorbance spectrophotometric detection	Moderate sample throughput. Automated in clinical chemistry analyzers. Interference from rare hemoglobin variants.	[130]
Glycated hemoglobin HbA ₁	Boronate affinity chromatography with absorbance spectrophotometric detection	Moderate sample throughput. Measures sum of HbA _{1a} , HbA _{1b} and HbA _{1c} . Automated in clinical chemistry analyzers. Minimal interference from hemoglobin variants.	[131]
Glycated albumin	Enzymatic chromogenic assay (ketoamine oxidase/peroxidase)	Moderate sample throughput. Requires prior processing of glycated amino acids followed by proteolytic digestion.	[132]
Glycated albumin	Boronate affinity chromatography with absorbance spectrophotometric detection	Moderate throughput. Measures percentage albumin with fructosamine residues	[133]
Serum fructosamine	Absorbance spectrophotometry	Rapid and high sample throughput. Automated in clinical chemistry analyzers. Interferences: hemoglobin, bilirubin, glutathione, cysteine.	[63,134]
<i>Research application</i>			
All glycation analytes	Stable isotopic dilution analysis LC-MS/MS	Reference method. Moderate throughput. Multiplexing at minimal additional cost and without interference. Prior enzymatic hydrolysis for glycated proteins. Not yet fully automated. Limited commercial availability of analytical standards.	[9,14,96]
All glycation analytes	Immunoassay	High throughput. Different response for glycation adduct residues of proteins and glycation free adducts, requiring separation in pre-analytic processing. Often incomplete characterization of epitope specificity and calibration standards. Masked epitopes and other sample matrix effects. Interference from analyte in blocking proteins – advise use of polythreonine. Expensive to multiplex and risk of interference. Limited commercial availability of specific antibodies other than for CML. Preferably corroborated by LC-M/MS.	[92, 135–137]
Fluorescent AGEs	HPLC with fluorimetric detection	Medium throughput. Prior enzymatic hydrolysis for glycated proteins. Limited commercial availability of calibration standards. Can be run in-line with LC-MS/MS.	[9,14,96]
	Fluorimetry: excitation 350 nm, emission 440 nm “AGE fluorescence”.	Multiple fluorophores. Interference from non-AGE fluorophores. Excitation 328 nm, emission 378 nm wavelengths have also been used.	[68,138]
STEPS TO CLINICAL TRANSLATION OF PROTEIN GLYCATION BIOMARKERS – including application of machine learning to develop classifier algorithms.			
Step	Requirements		
1. Analytical method development and standard operating procedure.	Analytical sensitivity and specificity – including investigation of interferences; linearity and dynamic range; internal and calibration standards; limits of detection and quantification; intrabatch and interbatch coefficients of variation; conditions for clinical sample collection, storage and pre-analytic processing; protocol for data analysis and quality control.		
2. Application to clinical studies.	Determine reference interval in control study group.		
3. Development of classifier algorithms.	Assay protein glycation biomarkers in case and control study groups, with power analysis for appropriate sample number. ^a Train and test algorithms with analytical data from independent subject groups, optimizing for accuracy of case and control classification.		
4. Further validation studies.	Applicability to subjects of different age, gender, ethnicity and effect of co-morbidities and treatment. Algorithms for diagnosis, risk of severity progression and response to therapy of a health disorder or disease.		

^a An introduction to power analysis in clinical diagnostics was given by Xia et al. [139].

subjects, increasing *ca.* 45% from 20 to 80 years of age [68]. This may reflect age-dependent decrease of glucose tolerance [69]. There was no age-dependent link to skin collagen FL in patients with T1DM, although levels correlated positively with A1C and were decreased with therapeutic improvement of glycemic control [68,70]. In patients with T1DM of the Diabetes Control and Complications Trial (DCCT), increased skin collagen furosine was associated with worsening of diabetic retinopathy, nephropathy and neuropathy [71]. A similar study explored association with measures of subclinical CVD, finding furosine predicted future increased coronary artery calcification (CAC) and change of left ventricular mass/end diastolic volume ratio [72]. This may reflect the progression of CVD with increased hyperglycemia [37,38].

Other fructosamine-modified proteins studied are glycated low density lipoprotein (LDL) and high density lipoprotein (HDL). They are investigational risk predictors of atherosclerosis and coronary heart disease (Table 3).

5. Proteins modified by advanced glycation endproducts

Proteins modified by AGEs are currently investigational clinical biomarkers, typically measured in plasma protein and skin collagen. In a validation study for application to epidemiological investigations, plasma protein GSP and MG-H1 showed the highest reliability in replicate samples and greatest stability with delayed processing and storage [73].

In healthy subjects, plasma protein GSP correlated positively with subject age [73]. In skin collagen, CML, CEL, MG-H1, GSP, pentosidine and “AGE fluorescence” (excitation 328 nm, emission 378 nm) correlated positively with age in healthy subjects [68,74]. GSP is a stable degradation product of FL and may provide an improved cumulative measure of glucose exposure and dysglycemia, relative to FL [75]. It is the major glycation crosslink in skin collagen and may contribute to age-related impairment of elastic properties in skin [76]. MG-H1 has a half-life of only 12 days under physiological conditions so its increase with age is likely reflecting exposure to increased MG or dicarbonyl stress with age [77,78].

In patients with T1DM, plasma protein CML correlated positively with A1C and mean 24 h plasma glucose, consistent with glycemic control biomarker FL being often the major precursor of CML [4]. Increased plasma protein CML and CEL were positively associated with arterial pulse pressure [79], increased CML, CEL and pentosidine were associated with increased risk of CVD and all-cause mortality [80] but CML and other AGEs were not linked to the risk of developing diabetic nephropathy [81,82]. In skin collagen, glycation-related analytes including CML, CEL, G-H1, GSP, MG-H1 and pentosidine were risk predictors of progression of retinopathy and neuropathy but not nephropathy, with GSP and MG-H1 major contributors [71]; and CML, MG-H1, GSP and pentosidine also predictors of surrogate clinical endpoints of CVD [72].

In patients with T2DM, an increased AGE score computed from

Table 3
Glycated proteins and free adducts as clinical biomarkers.

Health decline or disease (Type of biomarker)	Glycation analyte (adduct)	Diagnostic indication and biomarker characteristics	Reference
<i>Proteins with early-stage glycation by glucose</i>			
Diabetes and prediabetes (Diagnostic biomarker and therapeutic monitoring - glycemic control)	Glycated hemoglobin A1C (fructosamine)	Diagnosis: normal, A1C <5.7% (<39 mmol/mol); prediabetes, A1C 5.7–6.4% (39–47 mmol/mol); diabetes, A1C ≥ 6.5% (≥48 mmol/mol). Therapeutic monitoring (glycemic control): good, <7% (53 mmol/mol); moderate, <8% (53 mmol/mol); poor, ≥8% (53 mmol/mol). In widespread clinical use.	[15,16,19]
	Glycated albumin (fructosamine)	Diagnosis: normal glycemia 11–16%. In widespread clinical use, particularly where there are interferences in use of A1C. Likely interference from change in albumin synthesis, catabolism, TER and glomerular filtration.	[42,140]
Microvascular and macrovascular complications of diabetes (Risk predictor)	Glycated skin collagen (fructosamine)	Risk prediction: increased furosine linked to worsening of diabetic retinopathy, nephropathy and neuropathy and increased CAC and left ventricular mass/end diastolic volume ratio.	[71,72]
Cardiovascular disease (Risk predictor)	LDL (fructosamine)	Apolipoprotein B100 major protein; half-life 3 days. Glycated in 6 domains. Difficult to quantify at all sites. May be risk predictor of myocardial infarction and surrogate of small dense LDL	[141–145]
	HDL (fructosamine)	Apolipoprotein A-1 major protein; half-life 3.3 days. 3–5% glycation; sites - lys-12, lys-96, lys-133, lys-205 and lys-239 Difficult to quantify. May be surrogate marker of HDL instability	[91, 146–148]
<i>Advanced glycation endproducts-modified proteins</i>			
Healthy aging (Diagnostic marker)	Plasma protein (GSP)	Correlates positively with age.	[73]
	Skin collagen (CML, CEL, GSP, MG-H1, pentosidine)	AGEs increase with donor age. May be linked to skin aging and age-linked decline in glucose tolerance and dysglycemia	[68,74]
Diabetes (Diagnostic marker; glycemic control)	Plasma protein (CML, GSP)	CML correlated positively with A1C and mean 24 h plasma glucose. Plasma protein GSP increased with T2DM.	[4,73]
Microvascular and macrovascular complications of diabetes (Risk predictor)	Plasma protein (CML, CEL and pentosidine)	T1DM: Increased plasma protein AGEs associated with increased risk of CVD and all-cause mortality. T2DM: inverse link to PAD.	[80,83]
	Skin collagen (CML, CEL, G-H1, GSP MG-H1 and pentosidine)	Predicted risk of diabetic retinopathy, diabetic neuropathy and increased risk of CVD (CIMT, increased left ventricular mass, and increased LV mass/end diastolic volume ratio).	[71,72][71, 72]
CKD (Risk predictor)	Plasma protein and free adduct (pentosidine)	Risk predictor of all-cause mortality.	[87]
CVD (Risk predictor)	Plasma protein (MG-H1)	Increased mortality in nondiabetic women	[90]
<i>Glycation endproduct free adducts</i>			
Chronic kidney disease (Risk predictor)	Fractional excretion of free adducts (FL, CML, CEL MG-H1, CMA and Pentosidine)	Fractional excretion of glycation free adduct is increased in patients with diabetes at high risk of EDRF, supporting a precision medicine approach.	[8]
	Plasma free adducts (CML, CEL and MG-H1)	Logistic regression model for progression of diabetic kidney disease	[106]

Table 4
Influence of genetics on protein glycation.

Glycated protein(s)	Type of study	Observation	Reference
Glycated hemoglobin A1C	Twin study (non-diabetic subjects)	Population variation: 62% genetics; 23% environment; 14% age. Genetic influence extended to patients with T1DM.	[40]
	GWAS study (non-diabetic subjects)	60 loci influencing A1C, explaining 4%–14% of the trait variance: 19 genes of glycemic status, 22 genes of red blood cell pathways, 19 genes unclassified.	[32]
Glycated albumin GA	First degree relatives and GWAS (non-diabetic subjects)	Population variation: 48% genetics. Associated SNP: GCKR - SNPs identified accounted for 3.2% of the variation.	[44,45]
Glycation gap (GG)	Twin study (non-diabetic subjects)	Population variation: 69% genetics; 31% environment. Twenty percent heritability of A1C was common to GG.	[149]
Serum protein CML	Twin study (non-diabetic subjects)	Population variation: 74% genetics.	[150]

plasma protein CML, CEL and pentosidine was inversely linked to BMI, risk of PAD and GFR [62,83]. These associations may be due to increased albumin TER in obesity and PAD and increased loss of AGE-modified albumin through the glomerular filter with increased GFR [50,54]. Increased MG-H1 residue content of serum protein was associated with diabetic retinopathy in patients with T2DM [84]. Plasma protein CML was inversely associated with BMI in a large cohort of obese and insulin resistance subjects – some with T2DM [85], which may be due to increased albumin TER in obesity and insulin resistance [50–52] (Table 3).

Protein glycation biomarkers in CKD were recently reviewed elsewhere [86]. Total plasma pentosidine (protein-bound + free adduct), was a risk predictor of mortality in CKD after adjusting for all confounders [87] and may be reporting increased pentosephosphate pathway activity in response to oxidative stress induced by rapid decline in renal function and associated increased mortality [8]. CML residue

contents of plasma protein was investigated as a biomarker of mortality risk in renal failure in patients receiving hemodialysis therapy in two studies with contrary outcomes [88,89]. Whilst formation of AGEs likely has a role in the etiology of renal disease [86], there is interference in application of plasma protein glycation biomarkers from changes in albumin synthesis and protein loss in dialysis.

For CVD, plasma protein MG-H1 was associated with increased mortality in nondiabetic women [90]. These observations suggest dicarbonyl stress may have a key role in CVD, particularly through formation of MG-modified small, dense LDL and MG modified HDL with decreased stability and half-life in pro-atherogenic dyslipidemia [91, 92]. Supporting this, a genome wide association study found expression of glyoxalase 1 (Glo1) which metabolizes MG was negatively linked to risk of coronary heart disease [93]. Increased plasma protein CML and pentosidine were associated with poor diastolic and systolic heart function [94], which may be due to interference of decreased albumin




Fig. 2. Compartmentalization of albumin glycation in plasma and interstitial fluid and impaired renal tubular reuptake of glycation free adducts in early-stage diabetic kidney disease. a. Glycation of albumin by glucose – glycation kinetics and dynamics in vascular and extravascular compartments. Physiological data from Refs. [6,152]. Relative glycation kinetics deduced from: $r_{\text{Glycation}} = k [\text{Glucose}][\text{albumin}]$, k is the glycation rate constant and assuming $r_{\text{Glycation}}$ in the plasma compartment = 100%. Albumin TER is increased (5.6–7.6% per h) and plasma volume decreases by up to 10% in hypertension and overweight/obese subjects with metabolic syndrome; obesity increases total body interstitial fluid volume [49,50,153]. b. Schematic diagram of amino acid transporters of arginine and lysine uptake in the renal tubular epithelium and engagement with glycation free adducts. Renal proximal tubular reuptake by low affinity binding to cation transporter proteins: heterodimeric complex $b^{0,+}AT/rBAT$ on the apical surface (gene names SLC7A9 and SLC3A1, respectively) and high affinity cationic amino acid transporter 1 (CAT-1) and heterodimeric complexes of $\gamma + LAT1$, $\gamma + LAT2$ with 4F2hc on the basolateral surface (gene names SLC7A1, SLC7A7, SLC7A6 and SLC3A2, respectively) [99–103]. Reproduced from Refs. [8,48] with permission. Abbreviations: GRF, glomerular filtration rate; TER, transcapillary escape rate.

TER [95].

6. Glycation free adducts

Assay of glycation free adducts requires minimal pre-analytic processing and is robust with short analysis time using stable isotopic dilution analysis LC-MS/MS [9,14]. Increased glycation free adducts in plasma and urine may be biomarkers of increased exposure to protein glycation and/or increased proteolysis of long-lived extracellular matrix proteins that have accumulated long-lived, chemically stable glycation adducts throughout life [96]. Recent studies suggest renal handling of glycation free adducts provides a very sensitive measure of patients who develop rapid loss of renal function or “early decline in renal function” (EDRF).

Diabetic kidney disease (DKD) occurs in about 40% patients with diabetes [97]. In a subset of patients with EDRF, renal function declines rapidly such that after 5–20 years, patients require renal dialysis and with median survival thereafter of only 3 years. During renal function decline, there is also a progressive increase in risk of fatal CVD, 3 to 20-fold higher than the healthy population. It is estimated that 19% patients with T1DM and 28% patients with T2DM develop EDRF [98].

Improved treatment and care could be provided if patients at risk of future development of EDRF could be identified. In an investigation of glycation free adducts in plasma and urine of patients with T1DM, with and without future development of EDRF (assessed during 12 years of follow-up), we found urinary excretion of pentosidine was increased in patients with EDRF, compared to patients with stable renal function. Remarkably, fractional excretions of 6 lysine and arginine-derived glycation free adducts were higher in patients with EDRF, compared to patients with stable renal function. Lysine and arginine-derived glycation free adducts are thought to be taken up and moved across the renal tubular epithelium by low affinity binding to cation transporter proteins which also take up arginine and lysine. These are: heterodimeric complex $b^{0,+}AT/rBAT$ on the apical surface and CAT-1 and heterodimeric complexes of $\gamma + LAT1$, $\gamma + LAT2$ with 4F2hc on the basolateral surface [99–103]. Interestingly, in genome-wide association studies genetic polymorphism of $\gamma + LAT1$, $\gamma + LAT2$, $b^{0,+}AT$ (genes SLC7A7, SLC7A6, and SLC7A9) was associated with variation in eGFR and development of CKD [104,105]. Impaired tubular reuptake of glycation free adducts by lysine and arginine transporter proteins in patients with EDRF is likely involved (Fig. 2b). Increased fractional excretions of glycation adducts are potential risk predictors for EDRF in diabetes and possibly

progression of non-diabetic CKD [8]. In an alternative approach, a logistic regression model indicated that plasma concentrations of CML, CEL and MG-H1 free adducts, but not A1C, were linked to progression of diabetic kidney disease in patients with T1DM, assessed by thickening of the renal glomerular basement membrane [106] (Table 3).

7. Application of artificial intelligence machine learning for the development of diagnostic algorithms with protein glycation features

Combination of multiple measurements as features in trained and tested algorithms is a recently developed strategy to improve clinical diagnostic performance of glycation adduct biomarkers. Plasma protein content of AGEs, CML, CMA, 3-deoxyglucosone-derived hydroimidazolone (3DG-H) and oxidative damage marker, dityrosine (DT), provided features in a diagnostic algorithm for autism spectrum disorder (ASD) or autism [101]. Autism is a developmental disorder of childhood that affects 12 million people worldwide with a global prevalence of 0.62% [107], with higher prevalence in the USA (2.47%) [108] and Europe (1.15%) [109]. Plasma protein contents of CML, CMA and DT were higher and plasma protein content of 3DG-H lower in children with ASD, compared to children with normal development. A diagnostic algorithm combining these analytes gave a test with 88% accuracy. An important indicator of diagnostic performance is positive likelihood ratio LR+, which is the ratio of subjects with a positive test who have a health disorder or disease, compared to number of subjects with a positive test who do not. Similarly, negative likelihood ratio LR- is the ratio of subjects with a negative test who have a health disorder or disease, compared to number of subjects with a negative test who do not. LR+ >10 and LR- <0.1 is considered strong, often conclusive evidence for positive and negative diagnosis, respectively; and LR+ of 5–10 and LR- of 0.1–0.2 provides moderate evidence of positive and negative diagnosis, respectively [110]. For the autism blood test, LR+ = 5.7 and LR- = 0.095, suggesting moderate and strong, often conclusive evidence of presence and absence of ASD, respectively [101]. Regarding algorithm features, increased CML and CMA residues in plasma protein may reflect increased plasma protein glycation by glyoxal, sourced mainly from lipid peroxidation [14]. Recent studies have associated genetic polymorphism of fatty acid desaturase (FADS) 1/2 and elongation of very long-chain fatty acids protein-2 (ELOVL2) with risk of ASD [111]. This may indicate a disturbance of long chain polyunsaturated fatty acid metabolism with increased lipid peroxidation in ASD. DT residue content of plasma proteins, a marker of protein oxidative damage, was increased in subjects with ASD whereas other oxidative damage markers were not. DT residue formation occurs by reaction of tyrosine residues in proteins with ROS and dual oxidase DUOX [112]. DUOX has an important role in gut mucosal immunity, host-microbe homeostasis and signaling for neutrophil recruitment into allergic airways [113]. Gut microbiota may be influential in development of the behavioral phenotype in ASD [114]. Decrease of 3DG-H content of plasma protein in subjects with ASD may reflect decreased concentration of plasma 3-DG due to increased 3-DG reductase activity, as discussed [101]. With further validation, this may provide the basis of a simple blood test for autism diagnosis. This is an example of combination of biomarkers of protein glycation and oxidative damage.

Application of glycation free adducts for clinical diagnosis is best developed for diagnosis and classification of early-stage arthritis. Protein glycation and oxidative damage accumulates in articular cartilage with age [115–117]. From the earliest stages, pathogenesis of arthritis involves increased proteolysis of articular cartilage. There are three main types of arthritis clinically: osteoarthritis (OA), rheumatoid arthritis (RA) and other inflammatory joint disease which is often self-resolving (non-RA). Arthritis type is often difficult to discern at the early stages. Early-stage detection may enable effective treatment of RA with disease-modifying anti-arthritis drugs and OA with beneficial lifestyle and therapeutic interventions. Early-stage arthritis was

Table 5

Application of artificial intelligence machine learning for the development of diagnostic algorithms involved glycation adducts.

Disorder or disease (Type of biomarker)	Analytes (adduct)	Diagnostic indication	Reference
Autism spectrum disorder (Diagnostic marker)	Glycated plasma protein (CML, CMA, 3DG-H and DT)	Combined in a diagnostic algorithm, gave moderate evidence for presence and borderline moderate/conclusive evidence for absence of ASD; LR+ = 5.7, LR- = 0.095.	[101]
Early-stage arthritis (Diagnosis marker)	Plasma free adducts (FL, CML, CEL, G-H1, MG-H1, 3DG-H, CEL, CMA, GSP, pentosidine; and MetSO, DT, NFK, 3-NT; and hyp and anti-CCP antibody status)	Diagnostic algorithm for early-stage arthritis (any type) vs good skeletal health: LR+ = 8.3 and LR- = 0.11. Diagnostic algorithm for classification of early-stage arthritis type (OA, RA and non-RA): for OA, RA and non-RA, LR+ = 16.1, 7.7 and 5.0 and LR- = 0.06, 0.34 and 0.36, respectively.	[116]
Early-stage decline in metabolic, vascular and renal health.	Urinary free adduct (FL; and val, age and BMI)	Diagnostic algorithm classifying good health vs early-stage health decline. LR+, 8.0.2.8 and 13.2, and LR- 0.24, 0.43 and 0.13 for metabolic, vascular and renal health respectively.	[151]

Interpretation of level of evidence from likelihood ratios: LR+: 1–2, minimal; 2–5, small; 5–10, moderate; >10, large and conclusive. LR-: 0.5–1.0, minimal; 0.2–0.5, small; 0.1–0.2, moderate; <0.1, large and conclusive [110].

detected and type assigned with diagnostic algorithms based on features of plasma glycation, oxidation and nitration free adducts in combination with hydroxyproline. LR+ and LR- for early-stage diagnosis was 10.2 and 0.09 respectively, indicating conclusive evidence for presence or absence of early-stage arthritis (any type). The type of arthritis could also be discerned where anti-citrullinated cyclic peptide (CCP) antibody positivity status was a feature [118]. This illustrates how combination of protein glycation, oxidative and nitration damage markers with the bone resorption biomarker, hyp, and anti-CCP antibody status – a clinical RA-biomarker requiring refinement, may provide high performance diagnosis.

A urinary health screen with age, BMI, FL free adduct and valine as features was also recently developed providing moderate, weak and strong evidence for early-stage decline in metabolic, vascular and renal health respectively (Table 5).

8. Overview and concluding remarks

A1C, GA and serum fructosamine are important clinical biomarkers in widespread use for assessment of glycemic control in patients with diabetes and A1C for also diagnosis of prediabetes and diabetes. Measurement of AGE residue content of skin collagen may provide an assessment of aging of skin and healthy aging, an indicator of glycemic control and risk prediction of vascular complication of diabetes. These are valuable clinical biomarkers because they reflect pathways mechanistically linked to the health disorder and disease phenotype: fructosamine, GSP and CML - hyperglycemia and glycemic control; MG-H1, CEL and G-H1 - dicarbonyl stress and metabolic dysfunction of unscheduled glycolysis linked mechanistically to the development of




Fig. 3. Biomarkers of glycation in clinical use and investigational development. See text for details. Key: solid line bordered filled arrows – glycation biomarkers in clinical use; dotted line bordered unfilled arrows - glycation biomarkers in investigational development. Abbreviations: A1C, glycated hemoglobin HbA_{1c}; anti-CCP Ab, anti-cyclic citrullinated peptide antibody; CMA, N^ε-carboxymethyl-arginine; 3DG-H, 3-deoxyglucosone-derived hydroimidazolone; and DT, dityrosine.

T2DM and diabetic vascular complications; and pentosidine - increased pentosephosphate pathway activity [9,28,119] (Table 1). Increased plasma glycation, oxidation and nitration free adducts combined with hyp and increased fractional excretion of glycation free adducts in diabetes with microalbuminuria may also be valuable diagnostic biomarkers of early-stage arthritis and risk predictors of DKD because they are close to the early-stage disease phenotype – increased joint proteolysis and decline in renal tubular function, respectively. Such biomarkers are likely to provide valuable diagnostic information and support a precision medicine approach. Protein glycation biomarkers are influenced by heritability, aging and decline in metabolic, vascular, renal and skeletal health and other factors. They are therefore applicable to populations of differing ethnicities, bridging the gap between genotype and phenotype [120], and thereby likely to find continued and expanding clinical use. A summary of established and emerging applications of protein glycation biomarkers is given: established biomarkers of glycemic control – A1C, glycated albumin and serum fructosamine; emerging biomarkers of risk prediction of vascular complications of diabetes, early-stage detection and classification of arthritis, a blood test for diagnosis of autism and, potentially, biomarkers of healthy aging (Fig. 3). For future research, with increased availability of analytical standards and LC-MS/MS assay platform for use or reference validation of immunoassays, and application of machine learning algorithm development for optimum biomarker combination and weighting, we call on collaborative efforts from the glycation research community with custodians of large clinical sample collections and computational scientists to develop and validate emerging and further innovate applications of protein glycation biomarkers for clinical diagnosis and screening, disease progression and therapeutic monitoring.

Declaration of competing interest

The authors declare that they have no conflict of interest in relation to the above manuscript.

Acknowledgements

The authors thank Qatar University and the Qatar Foundation for support for their glycation research.

References

- [1] J.E. Hodge, The Amadori rearrangement, *Adv. Carbohydr. Chem.* 10 (1955) 169–205.
- [2] E. Schleicher, L. Scheller, O.H. Wieland, Quantitation of lysine bound glucose of normal and diabetic erythrocyte membranes by HPLC analysis of furosine [ε-N-(L-furoylmethyl)-L-lysine], *Biochem. Biophys. Res. Commun.* 99 (1981) 1011–1019.
- [3] N. Ahmed, D. Dobler, M. Dean, P.J. Thornalley, Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity, *J. Biol. Chem.* 280 (2005) 5724–5732.
- [4] N. Ahmed, R. Babaei-Jadidi, S.K. Howell, P.J. Beisswenger, P.J. Thornalley, Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes, *Diabetologia* 48 (2005) 1590–1603.
- [5] N. Rabbani, P.J. Thornalley, Glycation research in *Amino Acids*: a place to call home, *Amino Acids* 42 (2012) 1087–1096.
- [6] M.P. Margaron, N. Soni, Serum albumin: touchstone or totem? *Anaesthesia* 53 (1998) 789–803.
- [7] S. Agalou, N. Ahmed, R. Babaei-Jadidi, A. Dawnay, P.J. Thornalley, Profound mishandling of protein glycation degradation products in uremia and dialysis, *J. Am. Soc. Nephrol.* 16 (2005) 1471–1485.
- [8] B.A. Perkins, N. Rabbani, A. Weston, A. Adaikalakoteswari, J.A. Lee, L. E. Lovblom, N. Cardinez, P.J. Thornalley, High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes, *Sci. Rep.* 10 (2020) 12709.
- [9] N. Rabbani, Paul J. Thornalley, Reading patterns of proteome damage by glycation, oxidation and nitration: quantitation by stable isotopic dilution analysis LC-MS/MS, *Essays Biochem.* 64 (2020) 169–183.
- [10] N. Ahmed, P.J. Thornalley, R. Luthen, D. Haussinger, K. Sebekova, R. Schinzel, W. Voelker, A. Heidland, Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis, *J. Hepatol.* 41 (2004) 913–919.
- [11] N. Rabbani, K. Sebekova, K. Sebekova Jr., A. Heidland, P.J. Thornalley, Protein glycation, oxidation and nitration free adduct accumulation after bilateral nephrectomy and ureteral ligation, *Kidney Int.* 72 (2007) 1113–1121.
- [12] M. Xue, M.O. Weickert, S. Qureshi, K. Ngianga-Bakwin, A. Anwar, M. Waldron, A. Shafie, D. Messenger, M. Fowler, G. Jenkins, N. Rabbani, P.J. Thornalley, Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation, *Diabetes* 65 (2016) 2282–2294.
- [13] A. Leong, E. Wheeler, Genetics of HbA1c: a case study in clinical translation, *Curr. Opin. Genet. Dev.* 50 (2018) 79–85.

- [14] P.J. Thornalley, N. Rabbani, Detection of oxidized and glycosylated proteins in clinical samples using mass spectrometry - a user's perspective, *Biochim. Biophys. Acta* 1840 (2014) 818–829.
- [15] American-Diabetes-Association, 6. Glycemic targets: standards of medical care in diabetes—2020, *Diabetes Care* 43 (2020) S66–S76.
- [16] American-Diabetes-Association, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020, *Diabetes Care* 43 (2020) S14–S31.
- [17] R. Shapiro, M.J. McManus, C. Zalut, H.F. Bunn, Sites of nonenzymatic glycosylation of human hemoglobin A, *J. Biol. Chem.* 255 (1980) 3120–3127.
- [18] N.B. Roberts, A.B. Amara, M. Morris, B.N. Green, Long-term evaluation of electrospray ionization mass spectrometric analysis of glycosylated hemoglobin, *Clin. Chem.* 47 (2001) 316–321.
- [19] S.H. Wang, T.F. Wang, C.H. Wu, S.H. Chen, In-depth comparative characterization of hemoglobin glycation in normal and diabetic bloods by LC-MS/MS, *J. Am. Soc. Mass Spectrom.* 25 (2014) 758–766.
- [20] R. Flückiger, H.B. Mortensen, Glycosylated haemoglobins, *J. Chromatogr. B Biomed. Sci. Appl.* 429 (1988) 279–292.
- [21] D. Prome, Y. Blouquit, C. Ponthus, J.C. Prome, J. Rosa, Structure of the human adult hemoglobin minor fraction-A_{1b} by electrospray and secondary ion mass spectrometry - pyruvic-acid as amino-terminal blocking group, *J. Biol. Chem.* 266 (1991) 13050–13054.
- [22] Y. Al-Abed, S. VanPatten, H. Li, J.A. Lawson, G.A. FitzGerald, K.R. Manogue, R. Bucala, Characterization of a novel hemoglobin-glutathione adduct that is elevated in diabetic patients, *Mol. Med.* 7 (2001) 619–623.
- [23] G. Delpierre, F. Collard, J. Fortpied, E. Van Schaftingen, Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes, *Biochem. J.* 365 (2002) 801–808.
- [24] G. Delpierre, D. Vertommen, D. Communi, M.H. Rider, E. Van Schaftingen, Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin, *J. Biol. Chem.* 279 (2004) 27613–27620.
- [25] D.M. Nathan, J. Kuenen, R. Borg, H. Zheng, D. Schoenfeld, R.J. Heine, Translating the A1C assay into estimated average glucose values, *Diabetes Care* 31 (2008) 1473–1478.
- [26] Y. Tahara, K. Shima, The response of hgb to stepwise plasma-glucose change over time in diabetic-patients, *Diabetes Care* 16 (1993) 1313–1314.
- [27] K.W. Beach, A theoretical model to predict the behavior of glycosylated hemoglobin levels, *J. Theor. Biol.* 81 (1979) 547–561.
- [28] D.E. Goldstein, R.R. Little, R.A. Lorenz, J.I. Malone, D. Nathan, C.M. Peterson, D. B. Sacks, Tests of glycemia in diabetes, *Diabetes Care* 27 (2004) 1761–1773.
- [29] E. Feskens, L. Brennan, P. Dussort, M. Flourakis, L.M.E. Lindner, D. Mela, N. Rabbani, W. Rathmann, F. Respondek, C. Stehouwer, S. Theis, P. Thornalley, S. Vinoy, Potential markers of dietary glycemic exposures for sustained dietary interventions in populations without diabetes, *Advances in Nutrition* 11 (2020) 1221–1236.
- [30] B.I. Freedman, A critical evaluation of glycosylated protein parameters in advanced nephropathy: a matter of life or death. Time to dispense with the hemoglobin A1C in end-stage kidney disease, *Diabetes Care* 35 (2012) 1621–1624.
- [31] M.E. Lacy, G.A. Wellenius, A.E. Sumner, A. Correa, M.R. Carnethon, R.I. Liem, J. G. Wilson, D.B. Sacks, D.R. Jacobs Jr., A.P. Carson, X. Luo, A. Gjelsvik, A. P. Reiner, R.P. Naik, S. Liu, S.K. Musani, C.B. Eaton, W.-C. Wu, Association of sickle cell trait with hemoglobin A1c in african Americans, *J. Am. Med. Assoc.* 317 (2017) 507–515.
- [32] E. Wheeler, A. Leong, C.-T. Liu, M.-F. Hivert, R.J. Strawbridge, C. Podmore, M. Li, J. Yao, X. Sim, J. Hong, A.Y. Chu, W. Zhang, X. Wang, P. Chen, N.M. Maruthur, B. C. Corneala, S.J. Sharp, Y. Jia, E.K. Kabagambe, L.-C. Chang, W.-M. Chen, C. E. Elks, D.S. Evans, Q. Fan, F. Giulianini, M.J. Go, J.-J. Hottenga, Y. Hu, A. U. Jackson, S. Kanoni, Y.J. Kim, M.E. Kleber, C. Ladenvall, C. Lecoeur, S.-H. Lim, Y. Lu, A. Mahajan, C. Marzi, M.A. Nalls, P. Navarro, I.M. Nolte, L.M. Rose, D. V. Rybin, S. Sanna, Y. Shi, D.O. Stram, F. Takeuchi, S.P. Tan, P.J. van der Most, J. V. Van Vliet-Ostapchouk, A. Wong, L. Yengo, W. Zhao, A. Goel, M.T. Martinez Larrad, D. Radke, P. Salo, T. Tanaka, E.P.A. van Iperen, G. Abecasis, S. Afaq, B. Z. Alizadeh, A.G. Bertoni, A. Bonnefond, Y. Böttcher, E.P. Bottinger, H. Campbell, O.D. Carlson, C.-H. Chen, Y.S. Cho, W.T. Garvey, C. Gieger, M.O. Goodarzi, H. Grallert, A. Hamsten, C.A. Hartman, C. Herder, C.A. Hsiung, J. Huang, M. Igase, M. Isono, T. Katsuya, C.-C. Khor, W. Kiess, K. Kohara, P. Kovacs, J. Lee, W.-J. Lee, B. Lehne, H. Li, J. Liu, S. Lobbens, J.a. Luan, V. Lyssenko, T. Meitinger, T. Miki, I. Miljkovic, S. Moon, A. Mulas, G. Müller, M. Müller-Nurasyid, R. Nagaraja, M. Nauck, J.S. Pankow, O. Polasek, I. Prokopenko, P.S. Ramos, L. Rasmussen-Torvik, W. Rathmann, S.S. Rich, N.R. Robertson, M. Roden, R. Roussel, I. Rudan, R.A. Scott, W.R. Scott, B. Sennblad, D.S. Siscovick, K. Strauch, L. Sun, M. Swertz, S.M. Tajuddin, K.D. Taylor, Y.-Y. Teo, Y.C. Tham, A. Tonjes, N.J. Wareham, G. Willensten, T. Wilsgaard, A.D. Hingorani, E.-C. Consortium, E.P.-I. Consortium, S. Lifelines Cohort, J. Egan, L. Ferrucci, G. K. Hovingh, A. Julia, M. Kivimaki, M. Kumari, I. Njolstad, C.N.A. Palmer, M. Serrano Rios, M. Stumvoll, H. Watkins, T. Aung, M. Blüher, M. Boehnke, D. I. Boomsma, S.R. Bornstein, J.C. Chambers, D.I. Chasman, Y.-D.I. Chen, Y.-T. Chen, C.-Y. Cheng, F. Cucca, E.J.C. de Geus, P. Deloukas, M.K. Evans, M. Fornage, Y. Friedlander, P. Froguel, L. Groop, M.D. Gross, T.B. Harris, C. Hayward, C.-K. Heng, E. Ingelsson, N. Kato, B.-J. Kim, W.-P. Koh, J.S. Kooner, A. Körner, D. Kuh, J. Kuusisto, M. Laakso, X. Lin, Y. Liu, R.J.F. Loos, P.K. E. Magnusson, W. März, M.I. McCarthy, A.J. Oldehinkel, K.K. Ong, N.L. Pedersen, M.A. Pereira, A. Peters, P.M. Ridker, C. Sabanayagam, M. Sale, D. Saleheen, J. Saltevo, P.E.H. Schwarz, W.H.H. Sheu, H. Snieder, T.D. Spector, Y. Tabara, J. Tuomilehto, R.M. van Dam, J.G. Wilson, J.F. Wilson, B.H.R. Wolfenbittel, T. Y. Wong, J.-Y. Wu, J.-M. Yuan, A.B. Zonderman, N. Soranzo, X. Guo, D.J. Roberts, J.C. Florez, R. Sladek, J. Dupuis, A.P. Morris, E.S. Tai, E. Selvin, J.I. Rotter, C. Langenberg, I. Barroso, J.B. Meigs, Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: a transethnic genome-wide meta-analysis, *PLoS Med.* 14 (2017), e1002383.
- [33] American-Diabetes-Association, 14. Management of diabetes in pregnancy: standards of medical care in diabetes-2020, *Diabetes Care* 43 (2020) S183–S192.
- [34] D.-C.-C.-T.R. Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, *New Engl. J. Med.* 327 (1993) 977–986.
- [35] D.M. Nathan, P.A. Cleary, J.-Y.C. Backlund, S.M. Genuth, J.M. Lachin, T. J. Orchard, P. Raskin, B. Zinman, C. Diabetes, I. Complications Trial/ Epidemiology of Diabetes, G. Complications Study Research, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes, *N. Engl. J. Med.* 353 (2005) 2643–2653.
- [36] I.M. Stratton, A.I. Adler, H.A.W. Neil, D.R. Matthews, S.E. Manley, C.A. Cull, D. Hadden, R.C. Turner, R.R. Holman, Association of glycaemic with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, *BMJ* 321 (2002) 405–412.
- [37] A.P. Carson, M.W. Steffes, J.J. Carr, Y. Kim, M.D. Gross, M.R. Carnethon, J. P. Reis, C.M. Loria, D.R. Jacobs, C.E. Lewis, Hemoglobin A1c and the progression of coronary artery calcification among adults without diabetes, *Diabetes Care* 38 (2015) 66–71.
- [38] F.C. Aepfelbacher, S.B. Yeon, L.A. Weinrauch, J. D'Elia, A.J. Burger, Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus, *Int. J. Cardiol.* 94 (2004) 47–51.
- [39] K.T. Khaw, N. Wareham, S. Bingham, R. Luben, A. Welch, N. Day, Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk, *Ann. Intern. Med.* 141 (2004) 413–420.
- [40] H. Snieder, P.A. Sawtell, L. Ross, J. Walker, T.D. Spector, R.D.G. Leslie, HbA1c Levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins, *Diabetes* 50 (2001) 2858–2863.
- [41] O.S. Barnaby, R.L. Cerny, W. Clarke, D.S. Hage, Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS, *Clin. Chim. Acta* 412 (2011) 1606–1615.
- [42] I. Shimizu, T. Kohzuma, M. Koga, A proposed glycemic control marker for the future: glycosylated albumin, *Journal of Laboratory and Precision Medicine* 4 (2019).
- [43] D.B. Sacks, D.M. Nathan, J.M. Lachin, Gaps in the glycation gap hypothesis, *Clin. Chem.* 57 (2011) 150–152.
- [44] S.J. Loomis, A. Tin, J. Coresh, E. Boerwinkle, J.S. Pankow, A. Köttgen, E. Selvin, P. Duggal, Heritability analysis of nontraditional glycemic biomarkers in the atherosclerosis risk in communities study, *Genet. Epidemiol.* 43 (2019) 776–785.
- [45] S.J. Loomis, M. Li, N.M. Maruthur, A.S. Baldrige, K.E. North, H. Mei, A. Morrison, A.P. Carson, J.S. Pankow, E. Boerwinkle, R. Scharpf, L.J. Rasmussen-Torvik, J. Coresh, P. Duggal, A. Köttgen, E. Selvin, Genome-wide association study of serum fructosamine and glycosylated albumin in adults without diagnosed diabetes: results from the atherosclerosis risk in communities study, *Diabetes* 67 (2018) 1684–1696.
- [46] D.G. Levitt, M.D. Levitt, Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements, *Int. J. Gen. Med.* 9 (2016) 229–255.
- [47] T. Cha, Y. Tahara, E. Yamoto, H. Yoneda, H. Ikegami, Y. Noma, K. Shima, T. Ogihara, Renal handling of glycosylated albumin in non-insulin-dependent diabetes mellitus with nephropathy, *Diabetes Res. Clin. Pract.* 12 (1991) 149–156.
- [48] J. Masania, M. Malczewska-Malec, U. Razny, J. Goralska, A. Zdzienicka, B. Kiec-Wilk, A. Gruca, J. Stancel-Mozwillo, A. Dembinska-Kiec, N. Rabbani, P. J. Thornalley, Dicarbonyl stress in clinical obesity, *Glycoconj. J.* 33 (2016) 581–589.
- [49] H.-H. Parving, F. Gynetberg, Transcapillary escape rate of albumin and plasma volume in essential hypertension, *Circ. Res.* 32 (1973) 643–652.
- [50] G. Dell'omo, G. Penno, L. Pucci, M. Mariani, S. Del Prato, R. Pedrinelli, Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome, *Atherosclerosis* 172 (2004) 383–389.
- [51] J.E. Nestler, C.O. Barlacini, G.A. Tetrault, M.J. Fratkin, J.N. Clore, W. G. Blackard, Increased transcapillary escape rate of albumin in nondiabetic men in response to hyperinsulinemia, *Diabetes* 39 (1990) 1212–1217.
- [52] J.A. O'Hare, J.B. Ferriss, Transcapillary escape rate of albumin and extracellular fluid volume in diabetes, *Diabetologia* 28 (1985) 937–938.
- [53] P.E. Ballmer, A.F. Ochsenein, S. Schütz Hofmann, Transcapillary escape rate of albumin positively correlates with plasma-albumin concentration in acute but not in chronic inflammatory disease, *Metabolism-Clinical and Experimental* 43 (1994) 697–705.
- [54] K. Kornerup, B.G. Nordestgaard, T.K. Jensen, B. Feldt-Rasmussen, J.P. Eiberg, K. S. Jensen, J.S. Jensen, Transendothelial exchange of low-density lipoprotein is unaffected by the presence of severe atherosclerosis, *Cardiovasc. Res.* 64 (2004) 337–345.
- [55] K. Matsumoto, K. Sano, R. Nagai, H. Suzuki, T. Kodama, M. Yoshida, S. Ueda, B. Smedsrod, S. Horiuchi, Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A, *Biochem. J.* 352 (2000) 233–240.
- [56] A. Tsutsui, A. Ogura, T. Tahara, S. Nozaki, S. Urano, M. Hara, S. Kojima, A. Kurbangalieva, H. Onoe, Y. Watanabe, N. Taniguchi, K. Tanaka, In vivo imaging of advanced glycation end products (AGEs) of albumin: first observations

- of significantly reduced clearance and liver deposition properties in mice, *Org. Biomol. Chem.* 14 (2016) 5755–5760.
- [57] D. Svistounov, A. Oteiza, S.N. Zykova, K.K. Sørensen, P. McCourt, A.J. McLachlan, R.S. McCuskey, B. Smedsrød, Hepatic disposal of advanced glycation end products during maturation and aging, *Exp. Gerontol.* 48 (2013) 549–556.
- [58] R. Nagai, K. Mera, K. Nakajou, Y. Fujiwara, Y. Iwao, H. Imai, T. Murata, M. Otagiri, The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs, *Biochim. Biophys. Acta* 1772 (2007) 1192–1198.
- [59] R. Nagai, K. Mera, Y. Fujiwara, M. Nagai, M. Otagiri, Comparison of pharmacokinetics between highly and mildly modified AGE proteins in mice, *Ann. N. Y. Acad. Sci.* 1126 (2008) 325–327.
- [60] Z. Irshad, M. Xue, A. Ashour, J.R. Larkin, P.J. Thornalley, N. Rabbani, Activation of the unfolded protein response in high glucose treated endothelial cells is mediated by methylglyoxal, *Sci. Rep.* 9 (2019) 7889.
- [61] A. Ashour, M. Xue, M. Al-Motawa, P.J. Thornalley, N. Rabbani, Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer, *BMJ Open Diabetes Research & Care* 8 (2020), e001458.
- [62] N. Rabbani, A. Adaikalakoteswari, K. Rossing, P. Rossing, L. Tarnow, H.-H. Parving, P.J. Thornalley, Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria, *Amino Acids* 42 (2012) 1627–1639.
- [63] R.N. Johnson, P.A. Metcalf, J.R. Baker, Fructosamine: a new approach to the estimation of serum glycosyl protein, An index of diabetic control, *Clin. Chim. Acta* 127 (1982) 87–95.
- [64] S.P. Juraschek, M.W. Steffes, E. Selvin, Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose, *Clin. Chem.* 58 (2012) 1648–1655.
- [65] P.J. Thornalley, A. Langborg, H.S. Minhas, Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose, *Biochem. J.* 344 (1999) 109–116.
- [66] R.M. Cohen, Y.R. Holmes, T.C. Chenier, C.H. Joiner, Discordance between HbA1c and fructosamine, *Diabetes Care* 26 (2003) 163–167.
- [67] S. Rodríguez-Segade, J. Rodríguez, J.M. Cabezas-Agricola, F.F. Gasanueva, F. Camiña, Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c), *Clin. Chem.* 57 (2011) 264–271.
- [68] D.G. Dyer, J.A. Dunn, S.R. Thorpe, K.E. Bailie, T.J. Lyons, D.R. McCance, J. W. Baynes, Accumulation of Maillard reaction products in skin collagen in diabetes and aging, *J. Clin. Invest.* 91 (1993) 2463–2469.
- [69] G.M. Reaven, N. Chen, C. Hollenbeck, Y.-D.I. Chen, Effect of age on glucose tolerance and glucose uptake in healthy individuals, *J. Am. Geriatr. Soc.* 37 (1989) 735–740.
- [70] T.J. Lyons, K.E. Bailie, D.G. Dyer, J.A. Dunn, J.W. Baynes, Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus, *J. Clin. Invest.* 87 (1991) 1910–1915.
- [71] S. Genuth, W. Sun, P. Cleary, X. Gao, D.R. Sell, J. Lachin, t.D.E.R. Group, V. M. Monnier, Skin advanced glycation endproducts (AGEs) glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes, *Diabetes* 64 (2015) 266–278.
- [72] V.M. Monnier, W. Sun, X. Gao, D.R. Sell, P.A. Cleary, J.M. Lachin, S. Genuth, D.E. R.G. The, Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes, *Cardiovasc. Diabetol.* 14 (2015) 118.
- [73] C.-J. Chiu, N. Rabbani, S. Rowan, M.-L. Chang, S. Sawyer, F.B. Hu, W. Willert, P. J. Thornalley, A. Anwar, L. Bar, J.H. Kang, A. Taylor, Studies of advanced glycation end products and oxidation biomarkers for type 2 diabetes, *Biofactors* 44 (2018) 281–288.
- [74] X. Fan, D.R. Sell, J. Zhang, I. Nemet, M. Theves, J. Lu, C. Strauch, M.K. Halushka, V.M. Monnier, Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: a comparative analysis, *Free Radic. Biol. Med.* 49 (2010) 847–856.
- [75] K.M. Biemel, D.A. Friedl, M.O. Lederer, Identification and quantification of major Maillard cross-links in human serum albumin and lens protein - evidence for glucosepane as the dominant compound, *J. Biol. Chem.* 277 (2002) 24907–24915.
- [76] C. Schulze, F. Wetzel, T. Kueper, A. Malsen, G. Muhr, S. Jaspers, T. Blatt, K. P. Wittern, H. Wenck, J.A. Kas, Stiffening of human skin fibroblasts with age, *Clin. Plast. Surg.* 39 (2012) 9–20.
- [77] N. Ahmed, O.K. Argirov, H.S. Minhas, C.A. Cordeiro, P.J. Thornalley, Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatisation by aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Ne-carboxymethyl-lysine- and Ne-(1-carboxyethyl)lysine-modified albumin, *Biochem. J.* 364 (2002) 1–14.
- [78] N. Rabbani, M. Xue, P.J. Thornalley, Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments, *Clin Sci* 130 (2016) 1677–1696.
- [79] M.T. Schram, C.G. Schalkwijk, A.H. Bootsma, J.H. Fuller, N. Chaturvedi, C.D. A. Stehouwer, Advanced glycation end products are associated with pulse pressure in type 1 diabetes - the EURODIAB Prospective Complications Study, *Hypertension* 46 (2005) 232–237.
- [80] J.W. Nin, A. Jorsal, I. Ferreira, C.G. Schalkwijk, M.H. Prins, H.H. Parving, L. Tarnow, P. Rossing, C.D. Stehouwer, Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes A 12-year follow-up study, *Diabetes Care* 34 (2011) 442–447.
- [81] R. Klein, K. Horak, K.E. Lee, L. Danforth, K.J. Cruickshanks, M.Y. Tsai, R. E. Gangnon, B.E.K. Klein, The relationship of serum soluble receptor for advanced glycation end products (sRAGE) and carboxymethyl lysine (CML) to the incidence of diabetic nephropathy in persons with type 1 diabetes, *Diabetes Care* 40 (2017) e117–e119.
- [82] B.A. Perkins, N. Rabbani, A. Weston, L.H. Ficociello, A. Adaikalakoteswari, M. Niewczas, J. Warram, A.S. Krolewski, P. Thornalley, Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes, *PLoS One* 7 (2012), e35655.
- [83] N.M.J. Hanssen, J.W.J. Beulens, S. van Dieren, J.L.J.M. Scheijen, D.L. van der A, A.M.W. Spijkerman, Y.T. van der Schouw, C.D.A. Stehouwer, C.G. Schalkwijk, Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 Years (EPIC-NL), *Diabetes* 64 (2015) 257–265.
- [84] D.S. Fosmark, P.A. Torjesen, B.K. Kilhovd, T.J. Berg, L. Sandvik, K.F. Hanssen, C. D. Agardh, E. Agardh, Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus, *Metabolism-Clinical and Experimental* 55 (2006) 232–236.
- [85] K.H.J. Gaens, I. Ferreira, M.P.H. van de Waarenburg, M.M. van Greevenbroek, C. J.H. van der Kallen, J.M. Dekker, G. Nijpels, S.S. Rensen, C.D.A. Stehouwer, C. G. Schalkwijk, Protein-bound plasma N-epsilon-(Carboxymethyl) lysine is inversely associated with central obesity and inflammation and significantly explain a part of the central obesity-related increase in inflammation the Hoorn and CODAM studies, *Arterioscler. Thromb. Vasc. Biol.* 35 (2015) 2707–2713.
- [86] N. Rabbani, P.J. Thornalley, Advanced glycation end products in the pathogenesis of chronic kidney disease, *Kidney Int.* 93 (2018) 803–813.
- [87] A. Machowska, J. Sun, A.R. Qureshi, N. Isoyama, P. Leurs, B. Anderstam, O. Heimbürger, P. Barany, P. Stenvinkel, B. Lindholm, Plasma pentosidine and its association with mortality in patients with chronic kidney disease, *PLoS One* 11 (2016), e0163826.
- [88] S.B. Schwedler, T. Metzger, R. Schinzel, C. Wanner, Advanced glycation end products and mortality in hemodialysis patients, *Kidney Int.* 62 (2002) 301–310.
- [89] Z. Wagner, M. Molnar, G.A. Molnar, M. Tamasko, B. Lacz, L. Wagner, B. Csiky, A. Heidland, J. Nagy, I. Wittmann, Serum carboxymethyllysine predicts mortality in hemodialysis patients, *Am. J. Kidney Dis.* 47 (2006) 294–300.
- [90] B.K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnema, P.A. Torjesen, K.F. Hanssen, M. Laako, Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women, *Atherosclerosis* 205 (2009) 590–594.
- [91] L. Godfrey, N. Yamada-Fowler, J.A. Smith, P.J. Thornalley, N. Rabbani, Arginine-directed glycation and decreased HDL plasma concentration and functionality, *Nutr. Diabetes* 4 (2014) e134.
- [92] N. Rabbani, L. Godfrey, M. Xue, F. Shaheen, M. Geoffron, R. Milne, P. J. Thornalley, Conversion of low density lipoprotein to the pro-atherogenic form by methylglyoxal with increased arterial proteoglycan binding and aortal retention, *Diabetes* 60 (2011) 1973–1980.
- [93] V.-P. Mäkinen, M. Civelek, Q. Meng, B. Zhang, J. Zhu, C. Levian, T. Huan, A. V. Segrè, S. Ghosh, J. Vivar, M. Nikpay, A.F.R. Stewart, C.P. Nelson, C. Willenborg, J. Erdmann, S. Blakenberg, C.J. O'Donnell, W. März, R. Laaksonen, S.E. Epstein, S. Kathiresan, S.H. Shah, S.L. Hazen, M.P. Reilly, A.J. Lusis, N. J. Samani, H. Schunkert, T. Quertermous, R. McPherson, X. Yang, T.L. Assimes, The coronary-Artery-Disease-genome-wide-replication-Meta-analysis-consortium, integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease, *PLoS Genet.* 10 (2014), e1004502.
- [94] P.B. Linssen, R.M. Henry, C.G. Schalkwijk, J.M. Dekker, G. Nijpels, H.-P.B.-L. Rocca, C.D. Stehouwer, Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: the Hoorn Study, *Diabetes Vasc. Dis. Res.* 13 (2016) 278–285.
- [95] B. Hesse, H. Parving, H. Lund-Jacobsen, I. Noer, Transcapillary escape rate of albumin and right atrial pressure in chronic congestive heart failure before and after treatment, *Circ. Res.* 39 (1976) 358–361.
- [96] P.J. Thornalley, S. Battah, N. Ahmed, N. Karachalias, S. Agalou, R. Babaei-Jadidi, A. Dawney, Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry, *Biochem. J.* 375 (2003) 581–592.
- [97] G. Pugliese, G. Penno, A. Natali, F. Barutta, S. Di Paolo, G. Rebollo, L. Gesualdo, L. De Nicola, Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”, *Nutr. Metabol. Cardiovasc. Dis.* 29 (2019) 1127–1150.
- [98] A.S. Krolewski, J. Skupien, P. Rossing, J.H. Warram, Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes, *Kidney Int.* 91 (2017) 1300–1311.
- [99] S. Grunwald, R. Krause, M. Bruch, T. Henle, M. Brandsch, Transepithelial flux of early and advanced glycation compounds across Caco-2 cell monolayers and their interaction with intestinal amino acid and peptide transport systems, *Br. J. Nutr.* 95 (2006) 1221–1228.
- [100] M. Hellwig, S. Geissler, R. Matthes, A. Peto, C. Silow, M. Brandsch, T. Henle, Transport of free and peptide-bound glycated amino acids: synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins, *Chembiochem* 12 (2011) 1270–1279.

- [101] A. Anwar, P.M. Abruzzo, S. Pasha, K. Rajpoot, A. Bolotta, A. Ghezzi, M. Marini, A. Posar, P. Visconti, P.J. Thornalley, N. Rabbani, Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis, *Mol. Autism*. 9 (2018) 3.
- [102] D. Fotiadis, Y. Kanai, M. Palacín, The SLC3 and SLC7 families of amino acid transporters, *Mol. Aspects Med.* 34 (2013) 139–158.
- [103] V. Makrides, S.M.R. Camargo, F. Verrey, Transport of Amino Acids in the Kidney, *Comprehensive Physiology*, American Physiological Society, New York, 2014, pp. 367–403.
- [104] J.C. Chambers, W. Zhang, G.M. Lord, P. van der Harst, D.A. Lawlor, J.S. Sehmi, D. P. Gale, M.N. Wass, K.R. Ahmadi, S.J.L. Bakker, J. Beckmann, H.J.G. Bilo, M. Bochud, M.J. Brown, M.J. Caulfield, J.M.C. Connell, H.T. Cook, I. Cotlarciuc, G.D. Smith, R. de Silva, G. Deng, O. Devuyst, L.D. Dikkeschei, N. Dimkovic, M. Dockrell, A. Dominiczak, S. Ebrahim, T. Eggermann, M. Farrall, L. Ferrucci, J. Floege, N.G. Forouhi, R.T. Gansevoort, X. Han, B. Hedblad, J.J.H. van der Heide, B.G. Heppkema, M. Hernandez-Fuentes, E. Hypponen, T. Johnson, P.E. de Jong, N. Kleefstra, V. Lagou, M. Lapsley, Y. Li, R.J.F. Loos, J.a. Luan, K. Luttrupp, C. Maréchal, O. Melander, P.B. Munroe, L. Nordfors, A. Parsa, L. Peltonen, B. W. Penninx, E. Perucha, A. Pouta, I. Prokopenko, P.J. Roderick, A. Ruokonen, N. J. Samani, S. Sanna, M. Schalling, D. Schlessinger, G. Schlieper, M.A.J. Seelen, A. R. Shuldiner, M. Sjögren, J.H. Smit, H. Snieder, N. Soranzo, T.D. Spector, P. Stenvinkel, M.J.E. Sternberg, R. Swaminathan, T. Tanaka, L.J. Ubink-Veltmaat, M. Uda, P. Vollenweider, C. Wallace, D. Waterworth, K. Zerres, G. Waeber, N. J. Wareham, P.H. Maxwell, M.I. McCarthy, M.-R. Jarvelin, V. Mooser, G. R. Abecasis, L. Lightstone, J. Scott, G. Navis, P. Elliott, J.S. Kooner, Genetic loci influencing kidney function and chronic kidney disease, *Nat. Genet.* 42 (2010) 373–375.
- [105] D.I. Chasman, C. Fuchsberger, C. Pattaro, A. Teumer, C.A. Böger, K. Endlich, M. Olden, M.-H. Chen, A. Tin, D. Taliun, M. Li, X. Gao, M. Gorski, Q. Yang, C. Hundertmark, M.C. Foster, C.M. O’Seaghdha, N. Glazer, A. Isaacs, C.-T. Liu, A. V. Smith, J.R. O’Connell, M. Struchalin, T. Tanaka, G. Li, A.D. Johnson, H. J. Gierman, M.F. Feitosa, S.-J. Hwang, E.J. Atkinson, K. Lohman, M.C. Cornelis, A. Johansson, A. Tönjes, A. Dehghan, J.-C. Lambert, E.G. Holliday, R. Sorice, Z. Kutalik, T. Lehtimäki, T. Esko, H. Deshmukh, S. Ulivi, A.Y. Chu, F. Murgia, S. Trompet, M. Imboden, S. Coassin, G. Pistis, C.A. Consortium, I. Consortium, C. A. Consortium, T.B. Harris Wtccc, L.J. Launer, T. Aspelund, G. Eiriksdottir, B. D. Mitchell, E. Boerwinkle, H. Schmidt, M. Cavalieri, M. Rao, F. Hu, A. Demirkan, B.A. Oostra, M. de Andrade, S.T. Turner, J. Ding, J.S. Andrews, B.I. Freedman, F. Giulianini, W. Koenig, T. Illig, C. Meisinger, C. Gieger, L. Zgaga, T. Zemunik, M. Boban, C. Minelli, H.E. Wheeler, W. Igl, G. Zaboli, S.H. Wild, A.F. Wright, H. Campbell, D. Ellinghaus, U. Nöthlings, G. Jacobs, R. Biffar, F. Ernst, G. Homuth, H.K. Kroemer, M. Nauck, S. Stracke, U. Völker, H. Völzke, P. Kovacs, M. Stumvoll, R. Mägi, A. Hofman, A.G. Uitterlinden, F. Rivadeneira, Y. S. Aulchenko, O. Polasek, N. Hastie, V. Vitart, C. Helmer, J.J. Wang, B. Stengel, D. Ruggiero, S. Bergmann, M. Kähönen, J. Viikari, T. Nikopensius, M. Province, S. Ketkar, H. Colhoun, A. Doney, A. Robino, B.K. Krämer, L. Portas, I. Ford, B. M. Buckley, M. Adam, G.-A. Thun, B. Paulweber, M. Haun, C. Sala, P. Mitchell, M. Ciullo, S.K. Kim, P. Vollenweider, O. Raitakari, A. Metspalu, C. Palmer, P. Gasparini, M. Pirastu, J.W. Jukema, N.M. Probst-Hensch, F. Kronenberg, D. Toniolo, V. Gudnason, A.R. Shuldiner, J. Coresh, R. Schmidt, L. Ferrucci, D. S. Siscovick, C.M. van Duijn, I.B. Borecki, S.L.R. Kardya, Y. Liu, G.C. Curhan, I. Rudan, U. Gyllenstein, J.F. Wilson, A. Franke, P.P. Pramstaller, R. Rettig, I. Prokopenko, J. Witteman, C. Hayward, P.M. Ridker, A. Parsa, M. Bochud, I. M. Heid, W.H.L. Kao, C.S. Fox, A. Köttgen, Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function, *Hum. Mol. Genet.* 21 (2012) 5329–5343.
- [106] P.J. Beisswenger, S.K. Howell, G.B. Russell, M.E. Miller, S.S. Rich, M. Mauer, Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products, *Diabetes Care* 36 (2013) 3234–3239.
- [107] M. Elsbagh, G. Divan, Y.-J. Koh, Y.S. Kim, S. Kauchali, C. Marcín, C. Montiel-Nava, V. Patel, C.S. Paula, C. Wang, M.T. Yasamy, E. Fombonne, Global prevalence of autism and other pervasive developmental disorders, *Autism Res.* 5 (2012) 160–179.
- [108] G. Xu, L. Strathearn, B. Liu, W. Bao, Prevalence of autism spectrum disorder among US children and adolescents, 2014–2016, *J. Am. Med. Assoc.* 319 (2018) 81–82.
- [109] A. Narzisi, M. Posada, F. Barbieri, N. Chericoni, D. Ciuffolini, M. Pinzino, R. Romano, M.L. Scattoni, R. Tancredi, S. Calderoni, F. Muratori, Prevalence of Autism Spectrum Disorder in a large Italian catchment area: a school-based population study within the ASDEU project, *Epidemiol. Psychiatr. Sci.* 29 (2018) 1–10.
- [110] R. Jaeschke, G.H. Guyatt, D.L. Sackett, G. Guyatt, E. Bass, P. Brill-Edwards, G. Browman, D. Cook, M. Farkouh, H. Gerstein, B. Haynes, R. Hayward, A. Holbrook, E. Juniper, H. Lee, M. Levine, V. Moyer, J. Nishikawa, A. Oxman, A. Patel, J. Philbrick, W.S. Richardson, S. Saave, D. Sackett, J. Sinclair, K.S. Trout, P. Tugwell, S. Tunis, S. Walter, M. Wilson, Users’ guides to the medical literature: III. How to use an article about a diagnostic test B. What are the results and will they help me in caring for my patients? *J. Am. Med. Assoc.* 271 (1994) 703–707.
- [111] C. Sun, M. Zou, X. Wang, W. Xia, Y. Ma, S. Liang, Y. Hao, L. Wu, S. Fu, FADS1-FADS2 and ELOVL2 gene polymorphisms in susceptibility to autism spectrum disorders in Chinese children, *BMC Psychiatr.* 18 (2018) 283.
- [112] D. Lévine, A. Modarressi, K.-H. Krause, B. Pittet-Cuénod, NADPH oxidase 4 deficiency leads to impaired wound repair and reduced dityrosine-crosslinking, but does not affect myofibroblast formation, *Free Radic. Biol. Med.* 96 (2016) 374–384.
- [113] Y.S. Bae, M.K. Choi, W.-J. Lee, Dual oxidase in mucosal immunity and host-microbe homeostasis, *Trends Immunol.* 31 (2010) 278–287.
- [114] M. Mussap, A. Noto, V. Fanos, Metabolomics of autism spectrum disorders: early insights regarding mammalian-microbial cometabolites, *Expert Rev. Mol. Diagn.* 16 (2016) 869–881.
- [115] N. Verzijl, J. DeGroot, E. Oldehinkel, R.A. Bank, S.R. Thorpe, J.W. Baynes, M. T. Bayliss, J.W.J. Bijlsma, F.P.J.G. Lafeber, J.M. TeKoppele, Age-related accumulation of Maillard reaction products in human articular cartilage collagen, *Biochem. J.* 350 (2000) 381–387.
- [116] C. Legrand, U. Ahmed, A. Anwar, K. Rajpoot, S. Pasha, C. Lambert, R.K. Davidson, I.M. Clark, P.J. Thornalley, Y. Henrotin, N. Rabbani, Glycation marker glucosepane increases with the progression of osteoarthritis and correlates with morphological and functional changes of cartilage in vivo, *Arthritis Res. Ther.* 20 (2018) 131.
- [117] M.C. Wells-Knecht, T.J. Lyons, D.R. McCance, S.R. Thorpe, J.W. Baynes, Age-dependent increases in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes, *J. Clin. Invest.* 100 (1997) 839–846.
- [118] U. Ahmed, A. Anwar, R.S. Savage, P.J. Thornalley, N. Rabbani, Protein oxidation, nitration and glycation biomarkers for early-stage diagnosis of osteoarthritis of the knee and typing and progression of arthritic disease, *Arthritis Res. Ther.* 18 (2016) 250.
- [119] N. Rabbani, P.J. Thornalley, Hexokinase-2 glycolytic overload in diabetes and ischemia-reperfusion injury, *Trends in Endocrinology & Metabolism* 30 (2019) 419–431.
- [120] C.P. Jenkinson, H.H.H. Göring, R. Arya, J. Blangero, R. Duggirala, R.A. DeFronzo, Transcriptomics in type 2 diabetes: bridging the gap between genotype and phenotype, *Genomics Data* 8 (2016) 25–36.
- [121] H.F. Erbersdobler, V. Faist, Metabolic transit of Amadori products, *Nahrung-Food* 45 (2001) 177–181.
- [122] N. Ahmed, R. Babaei-Jadidi, S.K. Howell, P.J. Thornalley, P.J. Beisswenger, Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes, *Diabetes Care* 28 (2005) 2465–2471.
- [123] K.J. Knecht, J.A. Dunn, K.F. McFarland, D.R. McCance, T.J. Lyons, S.R. Thorpe, J. W. Baynes, Effect of diabetes and aging on carboxymethyllysine levels in human urine, *Diabetes* 40 (1991) 190–196.
- [124] R. Liardon, D. de Weck-Gaudard, G. Philipposian, P.A. Finot, Identification of Nε-carboxymethyllysine: a new Maillard reaction product, in rat urine, *J. Agric. Food Chem.* 35 (1987) 427–431.
- [125] F. Wang, Y. Zhao, Y. Niu, C. Wang, M. Wang, Y. Li, C. Sun, Activated glucose-6-phosphate dehydrogenase is associated with insulin resistance by upregulating pentose and pentosidine in diet-induced obesity of rats, *Horm. Metab. Res.* 44 (2012) 938–942.
- [126] R. Meerwaldt, R. Graaff, P.H.N. Oomen, T.P. Links, J.J. Jager, N.L. Alderson, S. R. Thorpe, J.W. Baynes, R.O.B. Gans, A.J. Smit, Simple non-invasive assessment of advanced glycation endproduct accumulation, *Diabetologia* 47 (2004) 1324–1330.
- [127] A. Foerster, T. Henle, Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyralline, *Biochem. Soc. Trans.* 31 (2003) 1383–1385.
- [128] C. Hohmann, K. Liehr, C. Henning, R. Fiedler, M. Girndt, M. Gebert, M. Hulko, M. Storr, M.A. Glomb, Detection of free advanced glycation end products in vivo during hemodialysis, *J. Agric. Food Chem.* 65 (2017) 930–937.
- [129] W.G. John, M.R. Gray, D.L. Bates, J.L. Beacham, Enzyme immunoassay—a new technique for estimating hemoglobin A1c, *Clin. Chem.* 39 (1993) 663–666.
- [130] S. Eckerbom, Y. Bergqvist, J.-O. Jeppsson, Improved method for analysis of glycated haemoglobin by ion exchange chromatography, *Ann. Clin. Biochem.* 31 (1994) 355–360.
- [131] W.G. John, R. Little, D.B. Sacks, C. Weykamp, E. Linters-Westra, T. Hornsby, Z. Zhao, C. Siebelder, A. Tennill, E. English, Multicentre evaluation of the premier Hb210 HbA1c analyser, *Clin. Chem. Lab. Med.* 53 (2015) 319–327.
- [132] T. Kohzuma, T. Yamamoto, Y. Uematsu, Z.K. Shihabi, B.I. Freedman, Basic performance of an enzymatic method for glycated albumin and reference range determination, *J. Diabetes Sci. Technol.* 5 (2011) 1455–1462.
- [133] K. Shima, N. Ito, F. Abe, M. Hirota, M. Yano, Y. Yamamoto, T. Uchida, K. Noguchi, High-performance liquid-chromatographic assay of serum glycated albumin, *Diabetologia* 31 (1988) 627–631.
- [134] R.P. Hill, E.J. Hindle, J.E. Howey, M. Lemon, D.R. Lloyd, Recommendations for adopting standard conditions and analytical procedures in the measurement of serum fructosamine concentration, *Ann. Clin. Biochem.* 27 (1990) 413–424.
- [135] R. Nagai, S. Horiuchi, Application of monoclonal antibody libraries for the measurement of glycation adducts, *Biochem. Soc. Trans.* 31 (2003) 1438–1440.
- [136] W. Koito, T. Araki, S. Horiuchi, R. Nagai, Conventional antibody against Nε-(carboxymethyl)lysine (CML) shows cross-reaction to Nε-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody, *J. Biochem.* 136 (2004) 831–837.
- [137] X. Zhang, M. Frischmann, R. Kientsch-Engel, K. Steinmann, H. Stopper, T. Niwa, M. Pischetsrieder, Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients, *Clin. Chem. Lab. Med.* 43 (2005) 503.
- [138] V.M. Monnier, R.R. Kohn, A. Cerami, Accelerated AGE-related browning of human collagen in diabetes mellitus, *Proc. Natl. Acad. Sci. U.S.A.* 81 (1984) 583–587.
- [139] J. Xia, D.L. Broadhurst, M. Wilson, D.S. Wishart, Translational biomarker discovery in clinical metabolomics: an introductory tutorial, *Metabolomics* (2012) 1–20.

- [140] J. Anguizola, R. Matsuda, O.S. Barnaby, K.S. Hoy, C. Wa, E. DeBolt, M. Koke, D. S. Hage, Review: glycation of human serum albumin, *Clin. Chim. Acta* 425 (2013) 64–76.
- [141] G. Misciagna, G. Logroscino, G. De Michele, V. Guerra, A.M. Cisternino, M. G. Caruso, M. Trevisan, Glycated apolipoprotein B and myocardial infarction, *Nutr. Metabol. Cardiovasc. Dis.* 17 (2007) 6–12.
- [142] N. Rabbani, M. Varma Chittari, C.W. Bodmer, D. Zehnder, A. Ceriello, P. J. Thornalley, Increased glycation and oxidative damage to apolipoprotein B100 of LDL in patients with type 2 diabetes and effect of metformin, *Diabetes* 59 (2010) 1038–1045.
- [143] E. Schleicher, T. Deufel, O.H. Wieland, Non-enzymatic glycation of human serum lipoproteins: elevated epsilon-lysine glycosylated low-density lipoprotein in diabetic patients, *FEBS Lett.* 129 (1981) 1–4.
- [144] X. Wang, R. Bucala, R. Milne, Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products, *Proc. Natl. Acad. Sci. USA* 95 (1998) 7643–7647.
- [145] N. Younis, V. Charlton-Menys, R. Sharma, H. Soran, P.N. Durrington, Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro, *Atherosclerosis* 202 (2009) 162–168.
- [146] C. Calvo, N. Ulloa, M. Campos, C. Verdugo, M. Ayrault-Jarrier, The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo, *Clin. Chim. Acta* 217 (1993) 193–198.
- [147] S.R. Kashyap, A. Osme, S. Ilchenko, M. Golizeh, K. Lee, S. Wang, J. Bena, S. F. Previs, J.D. Smith, T. Kasumov, Glycation reduces the stability of ApoAI and increases HDL dysfunction in diet-controlled type 2 diabetes, *J. Clin. Endocrinol. Metab.* 103 (2017) 388–396.
- [148] C. Calvo, C. Talussot, G. Ponsin, F. Berthezene, Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties, *Biochem. Biophys. Res. Commun.* 153 (1988) 1060–1067.
- [149] R.M. Cohen, H. Snieder, C.J. Lindsell, H. Beyan, M.I. Hawa, S. Blinko, R. Edwards, T.D. Spector, R.D. Leslie, Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins, *Diabetes Care* 29 (2006) 1739–1743.
- [150] R.D.G. Leslie, H. Beyan, P. Sawtell, B.O. Boehm, T.D. Spector, H. Nieder, Level of an advanced glycation end product is genetically determined: a study of normal twins, *Diabetes* 52 (2003) 2441–2444.
- [151] J. Masania, G. Faustmann, A. Anwar, H. Hafner-Giessauf, R. Rajpoot, J. Grabher, K. Rajpoot, B. Tiran, B. Obermayer-Pietsch, B.M. Winklhofer-Roob, J.M. Roob, N. Rabbani, P.J. Thornalley, Urinary Metabolomic Markers of Protein Glycation, Oxidation and Nitration in Early-Stage Decline in Metabolic, Vascular and Renal Health, *Oxidative Medicine and Cellular Longevity*, 2019, 4851323.
- [152] D.G. Maggs, R. Jacob, F. Rife, R. Lange, P. Leone, M.J. During, W.V. Tamborlane, R.S. Sherwin, Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadriceps muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle, *J. Clin. Invest.* 96 (1995) 370–377.
- [153] G. Bhave, E.G. Neilson, Body fluid dynamics: back to the future, *J. Am. Soc. Nephrol.* 22 (2011) 2166–2181.